Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase 2 3Phase NA 2Phase 4 2Phase 3 2Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 149Gastrointestinal 31Gynecologic 26Breast 26Genitourinary 25Head & Neck 23Dermatologic 15Endocrine 13Sarcoma 9Other solid neoplasm 6NET 5Lymphoid 3CNS 3Plasma cell 2Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 481Leukemia 287Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Leukemia, Lymphocytic, Chronic, B-Cell 235Myelodysplastic Syndromes 200Lymphoma 148Lymphoma, Non-Hodgkin 143Hematologic Neoplasms 139Recurrence 109Lymphoma, Mantle-Cell 102Lymphoma, Follicular 100Lymphoma, Large B-Cell, Diffuse 96Multiple Myeloma 82Leukemia, Myelogenous, Chronic, BCR-ABL Positive 81Leukemia, Myelomonocytic, Chronic 77Lymphoma, B-Cell, Marginal Zone 75Burkitt Lymphoma 72Hodgkin Disease 69Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 52Lymphoma, B-Cell 50Neoplasms 47Waldenstrom Macroglobulinemia 46Myeloproliferative Disorders 44Blast Crisis 41Lymphoma, Large-Cell, Immunoblastic 38Leukemia, Myeloid, Chronic-Phase 35Leukemia, B-Cell 34Leukemia, Myeloid, Accelerated Phase 33Congenital Abnormalities 32Leukemia, Biphenotypic, Acute 31

Interventions

sargramostim 1pembrolizumab 1Tretinoin 1Nivolumab 1Monatide (IMS 3015) 1INCB059872 1Granulocyte-Macrophage Colony-Stimulating Factor 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Small Cell Lung Carcinoma × Other hematologic neoplasm × Clear all
NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡